SEZL Jumps 15% as EPS Growth Estimate Hits 27.3%
Sezzle (SEZL) led today's EPS-revision gainers with a 15.2% rally to $130.05 after our screener detected a 27.3% next-year EPS growth estimate on Oct 6, reinforced by its Nov 4 Q3 earnings date announcement. Novavax (NVAX) rose 14.3% on a +20.0pp upward revision to 97.3% growth, AGBK added 13.4% on a 44.5% estimate, while Vera Bradley (VRA) and Snap (SNAP) gained 12.4% and 11.7% respectively on upward EPS revisions.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| SEZL | Financial | 2026-10-06 | N/A | +15.2% |
| NVAX | Healthcare | 2026-10-07 | +20.0pp | +14.3% |
| AGBK | Financial | 2026-10-08 | N/A | +13.4% |
| VRA | Consumer Cyclical | 2026-10-09 | +63.6pp | +12.4% |
| SNAP | Communication Services | 2026-10-07 | +12.0pp | +11.7% |
Why did SEZL stock jump in October 2026?
SEZL jumped 15.2% (from $112.84 to $130.05) after our screener caught a 27.3% next-year EPS growth estimate on October 6, and the October 8 announcement of its November 4 Q3 results call reinforced the move.
Sezzle built on momentum that has made it the best-performing consumer finance stock of 2026, with shares up more than 77% year-to-date versus a modest 0.6% gain for peer Affirm. TD Cowen trimmed its price target on SEZL in an October 7 Q3 preview but kept a favorable stance, and the subsequent conference slate—BMO, Citi, KBW, TD Cowen and Needham over November 9–December 9—kept the story in front of institutional investors. The estimate revision, not the price-target tweak, was the primary trigger.
SEZL EPS revision history → · Screener snapshot from 2026-10-06 →
FAQ: SEZL
Why did SEZL stock jump?
SEZL rose 15.2% from $112.84 to $130.05 after our screener detected a 27.3% next-year EPS growth estimate on October 6, reinforced by its October 8 announcement of a November 4 Q3 earnings call.
What caused Sezzle's surge in October 2026?
The surge followed an EPS growth estimate of 27.3% for next year, plus a bullish setup for the Q3 report and five investor conferences scheduled between November 9 and December 9.
Is SEZL a buy after the rally?
The bull case rests on 27.3% next-year EPS growth and a 77% year-to-date gain with a November 4 Q3 print as the next catalyst; the stock has already moved 15.2% from its $112.84 detection price.
Why did NVAX stock jump in October 2026?
NVAX jumped 14.3% (from $11.22 to $12.82) after analysts raised the company's next-year EPS growth estimate from 77.3% to 97.3% on October 7.
The +20.0 percentage point revision—one of the largest moves on our screener that day—lands with no company-specific news in the window, so the move reflects estimate momentum rather than a headline. Novavax sits in the vaccine and biotech cohort, where shifting immunization expectations and expense discipline can swing forward EPS projections sharply. With no earnings release announced, the revision itself and the market's confirmation provide the full explanation for the gain.
NVAX EPS revision history → · Screener snapshot from 2026-10-07 →
FAQ: NVAX
Why did NVAX stock jump?
NVAX jumped 14.3% from $11.22 to $12.82 after analysts raised the next-year EPS growth estimate from 77.3% to 97.3% on October 7.
What is NVAX's EPS growth estimate?
Novavax's next-year EPS growth estimate now stands at 97.3%, up from 77.3% the prior week—a 20.0 percentage point revision.
Is NVAX a buy after the rally?
The revision supports the bull case, but with no earnings news in the window, NVAX remains a pure estimate-momentum trade that has already gained 14.3% from its $11.22 detection price.
Why did AGBK stock jump in October 2026?
AGBK jumped 13.4% (from $6.51 to $7.38) after our screener flagged a 44.5% next-year EPS growth estimate on October 8.
The financial-sector small cap moved without any earnings-related news in the window, meaning the revision alone drove the re-rating and the market quickly validated it. A 44.5% growth estimate is far above typical financial-sector norms, which helps explain the sharp reaction in the share price. The gain is a textbook example of an EPS-revision signal being confirmed by price action rather than by an accompanying press release.
AGBK EPS revision history → · Screener snapshot from 2026-10-08 →
FAQ: AGBK
Why did AGBK stock jump?
AGBK rose 13.4% from $6.51 to $7.38 after our screener detected a 44.5% next-year EPS growth estimate on October 8.
What is AGBK's EPS growth estimate?
AGBK's next-year EPS growth estimate is 44.5%, well above its financial-sector peers.
Is AGBK a buy after the rally?
The 44.5% EPS growth estimate is the key data point, but with no company news in the window, AGBK is a estimate-momentum play that has already run 13.4% from $6.51.
Why did VRA stock jump in October 2026?
VRA jumped 12.4% (from $5.14 to $5.78) after analysts more than doubled the company's next-year EPS growth estimate from 86.4% to 150.0% on October 9.
That +63.6 percentage point revision is the largest on today's list and points to a sharp turn in profitability expectations for the consumer cyclical brand. With no earnings-related news in the window, the move is a clean estimate-revision story: the screener caught the change and the market repriced the stock accordingly. Vera Bradley's low share price and small float can amplify percentage moves when estimates shift this dramatically.
VRA EPS revision history → · Screener snapshot from 2026-10-09 →
FAQ: VRA
Why did VRA stock jump?
VRA jumped 12.4% from $5.14 to $5.78 after analysts raised the next-year EPS growth estimate from 86.4% to 150.0% on October 9.
What is VRA's EPS growth estimate?
Vera Bradley's next-year EPS growth estimate is now 150.0%, up from 86.4%—a 63.6 percentage point revision.
Is VRA a buy after the rally?
The 150% growth estimate is the bullish anchor, but with no company news in the window, VRA is an estimate-driven move that has already gained 12.4% from $5.14.
Why did SNAP stock jump in October 2026?
SNAP jumped 11.7% (from $5.81 to $6.49) after analysts nudged its next-year EPS growth estimate from 399.7% to 411.7% on October 7.
The revision alone is small, but activist pressure added fuel: Blue Duck Capital's October 6 open letter urged the board to raise external capital for Specs, arguing a sum-of-the-parts re-rating could double the stock to $12–14 and free $500 million in annual Specs spending. Snap also set its Q3 2026 results call for October 8, keeping the turnaround narrative front and center. Of the five names here, SNAP is the one where news and estimate revision compounded.
SNAP EPS revision history → · Screener snapshot from 2026-10-07 →
FAQ: SNAP
Why did SNAP stock jump?
SNAP rose 11.7% from $5.81 to $6.49 after its next-year EPS growth estimate was revised from 399.7% to 411.7% on October 7, amplified by activist pressure on the Specs business.
What caused Snap's surge in October 2026?
A Blue Duck Capital open letter on October 6 urged Snap to raise external capital for Specs, claiming the move could double the stock to $12–14 and remove $500 million in annual Specs spending.
What is SNAP's EPS growth estimate?
Snap's next-year EPS growth estimate is 411.7%, up from 399.7% the prior week, reflecting expectations of a massive profit rebound.
Today's leaders cluster in financials and micro-cap cyclicals, with SEZL and AGBK showing that upward EPS revisions are being rewarded fastest where the float is small and estimates move sharply. The mix of pure revision stories (NVAX, AGBK, VRA) and revision-plus-catalyst setups (SEZL, SNAP) suggests investors are still paying up for positive earnings revisions even without confirmed news.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →